MOCLOBEMIDE IN SOCIAL PHOBIA - A PILOT OPEN STUDY

被引：19

作者：

BISSERBE, JC ^{[1
]}

LEPINE, JP ^{[1
]}

LEGOUBEY, P ^{[1
]}

RIGAUD, P ^{[1
]}

ALBERT, E ^{[1
]}

CHNEWEISS, L ^{[1
]}

RIOUX, P ^{[1
]}

机构：

[1] HOP BICHAT,PRATICIEN HOSP,PARIS,FRANCE

来源：

CLINICAL NEUROPHARMACOLOGY | 1994年 / 17卷

关键词：

MONOAMINE OXIDASE INHIBITOR; MOCLOBEMIDE; SOCIAL PHOBIA;

D O I：

10.1097/00002826-199417001-00010

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In an open-label pilot study, 35 outpatients with social phobia (DSM-III-R) received moclobemide for 12 weeks. The dosing range was 300-600 mg/ day. Eighteen patients completed the study and 28 received at least 4 weeks of treatment. There was a consistent improvement in the efficacy parameters. Moclobemide was effective in both major components of social phobia (fear and avoidance). Moclobemide seems as effective as conventional irreversible monoamine oxidase inhibitors. Tolerability was good apart from one occurrence of grand mal seizure.

引用

页码：S88 / S94

页数：7

共 18 条

[1]

AGRAS WS, 1990, J CLIN PSYCHIAT, V51, P52

[2] SOCIAL PHOBIA - A COMPARATIVE CLINICAL-STUDY [J].